Press Releases

Media Inquiries - media@caredxinc.com

Date	Title and Summary	Additional Formats
Toggle Summary Sep 17, 2019	CareDx to Participate in the Cantor Fitzgerald Global Healthcare Conference BRISBANE, Calif. , Sept. 17, 2019 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced	View HTML
Toggle Summary Sep 12, 2019	CareDx launches AlloSeq® cfDNA at ESOT 2019 CareDx will establish access to dd-cfDNA surveillance solutions for transplant patients worldwide BRISBANE, Calif. , Sept. 12, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically	View HTML
Toggle Summary Sep 11, 2019	CareDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif. , Sept. 11, 2019 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced	View HTML
Toggle Summary Aug 28, 2019	CareDx Acquires XynManagement Acquisition solidifies transplant leadership with transplant center quality management and patient waitlist management tools BRISBANE, Calif. , Aug. 28, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and	View HTML
Toggle Summary Aug 27, 2019	Chris Cournoyer Joins CareDx Board of Directors Cournoyer brings deep digital expertise to CareDx to support burgeoning digital solutions portfolio BRISBANE, Calif. , Aug. 27, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically	View HTML
Toggle Summary Aug 22, 2019	AlloSure for Heart Transplant Patients Receives CMS Draft Coverage CareDx expands leadership with cfDNA for transplant care BRISBANE, Calif. , Aug. 22, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions	View HTML
Toggle Summary Aug 21, 2019	Fear of Rejection is Transplant Patient’s Top Concern CareDx partnership with American Association of Kidney Patients yields key patient insights BRISBANE, Calif. , Aug. 21, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically	View HTML
Toggle Summary Aug 01, 2019	CareDx Reports Second Quarter 2019 Results AlloSure momentum drives 76% second quarter revenue growth BRISBANE, Calif. , Aug. 01, 2019 (GLOBE NEWSWIRE) -- CareDx , Inc. (NASDAQ: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare	View HTML
Toggle Summary Jul 16, 2019	CareDx to Announce Second Quarter 2019 Financial Results on August 1, 2019 BRISBANE, Calif. , July 16, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced	View HTML
Toggle Summary Jul 11, 2019	CareDx Applauds White House Efforts to Reform America’s Kidney Health System Executive Order outlines initiatives to make organ transplantation the preferred treatment option BRISBANE, Calif. , July 11, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading molecular diagnostics company focused on the discovery, development and commercialization of clinically	View HTML